• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Pavmed floats exchange offer for discounted Series W shares

February 12, 2018 By Sarah Faulkner

PavmedPavmed Inc. (NSDQ:PAVM) today offered to trade a pair of its just-sold Series W warrants for a single Series Z unit worth $5.oo apiece.

The New York-based company previously offered the opportunity for investors to exercise the Series W warrants at a discounted price of $2.00 per share. As of Feb. 8, Pavmed said 34,345 Series W warrants had been tendered for exercise and the company had raised $68,690 in gross cash proceeds.

Each of Pavmed’s outstanding Series W warrants can be exercised for one share of common stock at an exercise price of $5.00 per share until Jan. 29, 2022, while each Z warrant can be exercised for one share of common stock at $3.00 apiece until April 30, 2024.

Pavmed noted that if all W warrants are exchanged as part of its latest offer, the company’s common stock will be cut by 5,283,992 shares.

Pavmed also raised $3.9 million in public offering at the end of last month, saying that it planned to use the funds for working capital and general corporate purposes.

The company sold 2.4 million shares of its common stock at $1.80 apiece in the offering, which also included a 45-day option for underwriters to buy an additional 362,292 shares of common stock to cover over-allotments.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Wall Street Beat Tagged With: PAVmed

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS